TST001 clinical trials
TST001 is named as an intervention in 2 current clinical trials in our USA and China registers. None are recruiting at the moment. All registered phases are Phase 1/2. The lead sponsor is Transcenta Therapeutics (Hangzhou) Co., Ltd. The most-studied condition is Advanced Cancer.
How TST001 works
All drug targets →- Gastric adenocarcinomaPhase 3
- Gastroesophageal junction adenocarcinomaPhase 3
- Biliary tract cancerPhase 2
- Gastric cancerPhase 1/2
- Pancreatic adenocarcinomaPhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5095388, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for TST001
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of TST001
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
NCT04396821 · Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
|
Phase 1/2 | Active, closed | Transcenta Therapeutics (Hangzhou) Co., Ltd | USA |
|
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
NCT04495296 · ClinicalTrials.gov ↗ · Advanced Cancer
|
Phase 1/2 | Active, closed | Transcenta Therapeutics (Hangzhou) Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with TST001
4 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Transcenta Therapeutics (Hangzhou) Co., Ltd | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 1 | 0 |
| Clinical trials in China | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about TST001 trials
How many clinical trials are testing TST001?
2 current trials in our USA and China registers name TST001 as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are TST001 trials recruiting patients?
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Who sponsors TST001 clinical trials?
The lead sponsor is Transcenta Therapeutics (Hangzhou) Co., Ltd. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how TST001 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how TST001 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists TST001 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.